Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma.

Frontiers in oncology

Attarian F, Taghizadeh-Hesary F, Fanipakdel A, Javadinia SA, Porouhan P, PeyroShabany B, Fazilat-Panah D.
PMID: 34900732
Front Oncol. 2021 Nov 23;11:779491. doi: 10.3389/fonc.2021.779491. eCollection 2021.

BACKGROUND: In newly diagnosed glioblastoma, radiation with concurrent and adjuvant (six cycles) temozolomide (TMZ) is the established standard of postsurgical care. However, the benefit of extending adjuvant TMZ therapy beyond six cycles has remained unknown.METHODS: We searched PubMed, Web...

Cite
Attarian F, Taghizadeh-Hesary F, Fanipakdel A, et al. A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma. Front Oncol. 2021;11:779491doi: 10.3389/fonc.2021.779491.
Attarian, F., Taghizadeh-Hesary, F., Fanipakdel, A., Javadinia, S. A., Porouhan, P., PeyroShabany, B., & Fazilat-Panah, D. (2021). A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma. Frontiers in oncology, 11779491. https://doi.org/10.3389/fonc.2021.779491
Attarian, Fahimeh, et al. "A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma." Frontiers in oncology vol. 11 (2021): 779491. doi: https://doi.org/10.3389/fonc.2021.779491
Attarian F, Taghizadeh-Hesary F, Fanipakdel A, Javadinia SA, Porouhan P, PeyroShabany B, Fazilat-Panah D. A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma. Front Oncol. 2021 Nov 23;11:779491. doi: 10.3389/fonc.2021.779491. eCollection 2021. PMID: 34900732; PMCID: PMC8651479.
Copy Download .nbib Format: NLM
A case report of prostate adenocarcinoma with leptomeningeal carcinomatosis and intracerebral metastasis.

Clinical case reports

Fazilat-Panah D, Ahmadi N, Moslemi D, Karimi M, Taji A, Dehghani M, Emadi Torghabeh A, Keshtpour Amlashi Z, Saghafi M, Fatemi MA.
PMID: 34745620
Clin Case Rep. 2021 Oct 28;9(10):e05000. doi: 10.1002/ccr3.5000. eCollection 2021 Oct.

Despite the fact that prostate cancer is the most prevalent cancer in men, metastases to the central nervous system including leptomeningeal involvement by prostate carcinoma is a rare event. The prognosis of metastatic prostate cancer is very poor due...

Cite
Fazilat-Panah D, Ahmadi N, Moslemi D, et al. A case report of prostate adenocarcinoma with leptomeningeal carcinomatosis and intracerebral metastasis. Clin Case Rep. 2021;9(10):e05000doi: 10.1002/ccr3.5000.
Fazilat-Panah, D., Ahmadi, N., Moslemi, D., Karimi, M., Taji, A., Dehghani, M., Emadi Torghabeh, A., Keshtpour Amlashi, Z., Saghafi, M., & Fatemi, M. A. (2021). A case report of prostate adenocarcinoma with leptomeningeal carcinomatosis and intracerebral metastasis. Clinical case reports, 9(10), e05000. https://doi.org/10.1002/ccr3.5000
Fazilat-Panah, Danial, et al. "A case report of prostate adenocarcinoma with leptomeningeal carcinomatosis and intracerebral metastasis." Clinical case reports vol. 9,10 (2021): e05000. doi: https://doi.org/10.1002/ccr3.5000
Fazilat-Panah D, Ahmadi N, Moslemi D, Karimi M, Taji A, Dehghani M, Emadi Torghabeh A, Keshtpour Amlashi Z, Saghafi M, Fatemi MA. A case report of prostate adenocarcinoma with leptomeningeal carcinomatosis and intracerebral metastasis. Clin Case Rep. 2021 Oct 28;9(10):e05000. doi: 10.1002/ccr3.5000. eCollection 2021 Oct. PMID: 34745620; PMCID: PMC8552091.
Copy Download .nbib Format: NLM
Opium poisoning following self-medication of radiation-induced dermatitis with topical use of opium latex traditional extract; a teaching case.

Clinical case reports

Dehghani M, Hosseini SM, Molkara S, Fazilat-Panah D, Mehrpour O, Soroosh D, Zarei E, Welsh JS, Nematshahi M, Javadinia SA.
PMID: 34430021
Clin Case Rep. 2021 Aug 16;9(8):e04661. doi: 10.1002/ccr3.4661. eCollection 2021 Aug.

Despite Radiation-induced dermatitis is a self-limiting complication, it can be complicated if inappropriate self-medications have been used such as opium latex traditional extract.

Cite
Dehghani M, Hosseini SM, Molkara S, et al. Opium poisoning following self-medication of radiation-induced dermatitis with topical use of opium latex traditional extract; a teaching case. Clin Case Rep. 2021;9(8):e04661doi: 10.1002/ccr3.4661.
Dehghani, M., Hosseini, S. M., Molkara, S., Fazilat-Panah, D., Mehrpour, O., Soroosh, D., Zarei, E., Welsh, J. S., Nematshahi, M., & Javadinia, S. A. (2021). Opium poisoning following self-medication of radiation-induced dermatitis with topical use of opium latex traditional extract; a teaching case. Clinical case reports, 9(8), e04661. https://doi.org/10.1002/ccr3.4661
Dehghani, Mansoureh, et al. "Opium poisoning following self-medication of radiation-induced dermatitis with topical use of opium latex traditional extract; a teaching case." Clinical case reports vol. 9,8 (2021): e04661. doi: https://doi.org/10.1002/ccr3.4661
Dehghani M, Hosseini SM, Molkara S, Fazilat-Panah D, Mehrpour O, Soroosh D, Zarei E, Welsh JS, Nematshahi M, Javadinia SA. Opium poisoning following self-medication of radiation-induced dermatitis with topical use of opium latex traditional extract; a teaching case. Clin Case Rep. 2021 Aug 16;9(8):e04661. doi: 10.1002/ccr3.4661. eCollection 2021 Aug. PMID: 34430021; PMCID: PMC8365850.
Copy Download .nbib Format: NLM
Changes in Cytokeratin 18 during Neoadjuvant Chemotherapy of Breast Cancer: A Prospective Study.

Iranian journal of pathology

Fazilat-Panah D, Vakili Ahrari Roudi S, Keramati A, Fanipakdel A, Sadeghian MH, Homaei Shandiz F, Shahidsales S, Javadinia SA.
PMID: 32215027
Iran J Pathol. 2020;15(2):117-126. doi: 10.30699/ijp.2020.116238.2261. Epub 2020 Feb 19.

BACKGROUND & OBJECTIVE: Prediction of response to neoadjuvant treatment is an important part of treatment of patients with breast cancer. This study aimed to assess changes in serum levels of Cytokeratin 18 during neoadjuvant chemotherapy in patients with locally...

Cite
Fazilat-Panah D, Vakili Ahrari Roudi S, Keramati A, et al. Changes in Cytokeratin 18 during Neoadjuvant Chemotherapy of Breast Cancer: A Prospective Study. Iran J Pathol. 2020;15(2):117-126doi: 10.30699/ijp.2020.116238.2261.
Fazilat-Panah, D., Vakili Ahrari Roudi, S., Keramati, A., Fanipakdel, A., Sadeghian, M. H., Homaei Shandiz, F., Shahidsales, S., & Javadinia, S. A. (2020). Changes in Cytokeratin 18 during Neoadjuvant Chemotherapy of Breast Cancer: A Prospective Study. Iranian journal of pathology, 15(2), 117-126. https://doi.org/10.30699/ijp.2020.116238.2261
Fazilat-Panah, Danial, et al. "Changes in Cytokeratin 18 during Neoadjuvant Chemotherapy of Breast Cancer: A Prospective Study." Iranian journal of pathology vol. 15,2 (2020): 117-126. doi: https://doi.org/10.30699/ijp.2020.116238.2261
Fazilat-Panah D, Vakili Ahrari Roudi S, Keramati A, Fanipakdel A, Sadeghian MH, Homaei Shandiz F, Shahidsales S, Javadinia SA. Changes in Cytokeratin 18 during Neoadjuvant Chemotherapy of Breast Cancer: A Prospective Study. Iran J Pathol. 2020;15(2):117-126. doi: 10.30699/ijp.2020.116238.2261. Epub 2020 Feb 19. PMID: 32215027; PMCID: PMC7081760.
Copy Download .nbib Format: NLM
A case report of mediastinal cavernous hemangioma.

Clinical case reports

Ouladdameshghi D, Eshraghi M, Shahhamzeh A, Riyah MM, Fatemi MA, Fazilat-Panah D, Dehghani M.
PMID: 34466254
Clin Case Rep. 2021 Aug 25;9(8):e04698. doi: 10.1002/ccr3.4698. eCollection 2021 Aug.

When faced with a hypervascular mediastinal tumor, mediastinal hemangioma should be taken into consideration. Although it is uncommon, considering this important diagnosis may avoid a possible extensive surgery that is not necessary.

Cite
Ouladdameshghi D, Eshraghi M, Shahhamzeh A, et al. A case report of mediastinal cavernous hemangioma. Clin Case Rep. 2021;9(8):e04698doi: 10.1002/ccr3.4698.
Ouladdameshghi, D., Eshraghi, M., Shahhamzeh, A., Riyah, M. M., Fatemi, M. A., Fazilat-Panah, D., & Dehghani, M. (2021). A case report of mediastinal cavernous hemangioma. Clinical case reports, 9(8), e04698. https://doi.org/10.1002/ccr3.4698
Ouladdameshghi, Davoud, et al. "A case report of mediastinal cavernous hemangioma." Clinical case reports vol. 9,8 (2021): e04698. doi: https://doi.org/10.1002/ccr3.4698
Ouladdameshghi D, Eshraghi M, Shahhamzeh A, Riyah MM, Fatemi MA, Fazilat-Panah D, Dehghani M. A case report of mediastinal cavernous hemangioma. Clin Case Rep. 2021 Aug 25;9(8):e04698. doi: 10.1002/ccr3.4698. eCollection 2021 Aug. PMID: 34466254; PMCID: PMC8385463.
Copy Download .nbib Format: NLM
A case report of prostate cancer with leptomeningeal metastasis.

Cancer reports (Hoboken, N.J.)

Dehghani M, PeyroShabany B, Shahraini R, Fazilat-Panah D, Hashemi F, Welsh JS, Javadinia SA.
PMID: 34089302
Cancer Rep (Hoboken). 2021 Jun 05;e1463. doi: 10.1002/cnr2.1463. Epub 2021 Jun 05.

BACKGROUND: Prostate cancer is the most prevalent cancer in men. However, leptomeningeal involvement by prostate carcinoma is a rare event.CASE: Here, we report a 69-year-old patient with castration-resistant metastatic prostate cancer who presented with headache and ataxia. Brain MRI...

Cite
Dehghani M, PeyroShabany B, Shahraini R, et al. A case report of prostate cancer with leptomeningeal metastasis. Cancer Rep (Hoboken). 2021;e1463doi: 10.1002/cnr2.1463.
Dehghani, M., PeyroShabany, B., Shahraini, R., Fazilat-Panah, D., Hashemi, F., Welsh, J. S., & Javadinia, S. A. (2021). A case report of prostate cancer with leptomeningeal metastasis. Cancer reports (Hoboken, N.J.), e1463. https://doi.org/10.1002/cnr2.1463
Dehghani, Mansoureh, et al. "A case report of prostate cancer with leptomeningeal metastasis." Cancer reports (Hoboken, N.J.) vol. (2021): e1463. doi: https://doi.org/10.1002/cnr2.1463
Dehghani M, PeyroShabany B, Shahraini R, Fazilat-Panah D, Hashemi F, Welsh JS, Javadinia SA. A case report of prostate cancer with leptomeningeal metastasis. Cancer Rep (Hoboken). 2021 Jun 05;e1463. doi: 10.1002/cnr2.1463. Epub 2021 Jun 05. PMID: 34089302.
Copy Download .nbib Format: NLM
Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic.

Cancer investigation

Javadinia SA, Ariamanesh M, Nabavifard M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Hatami F, Ghasemi A, Lyman GH, Welsh JS, Ashkar Tizabi S, Dehghani M.
PMID: 34699294
Cancer Invest. 2022 Feb;40(2):115-123. doi: 10.1080/07357907.2021.1995742. Epub 2021 Nov 11.

Patients with cancer are at significantly greater risk of COVID-19 and its complications than the general population. Since IgG antibodies remain detectable well after infection with the SARS-CoV-2 virus, seroprevalence can be used to estimate the proportion of the...

Cite
Javadinia SA, Ariamanesh M, Nabavifard M, et al. Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer Invest. 2021;40(2):115-123doi: 10.1080/07357907.2021.1995742.
Javadinia, S. A., Ariamanesh, M., Nabavifard, M., Porouhan, P., PeyroShabany, B., Fazilat-Panah, D., Hatami, F., Ghasemi, A., Lyman, G. H., Welsh, J. S., Ashkar Tizabi, S., & Dehghani, M. (2022). Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer investigation, 40(2), 115-123. https://doi.org/10.1080/07357907.2021.1995742
Javadinia, Seyed Alireza, et al. "Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic." Cancer investigation vol. 40,2 (2022): 115-123. doi: https://doi.org/10.1080/07357907.2021.1995742
Javadinia SA, Ariamanesh M, Nabavifard M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Hatami F, Ghasemi A, Lyman GH, Welsh JS, Ashkar Tizabi S, Dehghani M. Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer Invest. 2022 Feb;40(2):115-123. doi: 10.1080/07357907.2021.1995742. Epub 2021 Nov 11. PMID: 34699294.
Copy Download .nbib Format: NLM
Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy.

Cancer investigation

Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, Hatami F, Fereidouni M, Welsh JS, Javadinia SA.
PMID: 34634986
Cancer Invest. 2022 Jan;40(1):26-34. doi: 10.1080/07357907.2021.1992420. Epub 2021 Oct 26.

OBJECTIVE: To evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients.MATERIAL AND METHOD: 364 cancer patients who received two doses of vaccine were enrolled. The presence of SARS-CoV-2 anti-Spike protein IgG and neutralizing antibody 2...

Cite
Ariamanesh M, Porouhan P, PeyroShabany B, et al. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Invest. 2021;40(1):26-34doi: 10.1080/07357907.2021.1992420.
Ariamanesh, M., Porouhan, P., PeyroShabany, B., Fazilat-Panah, D., Dehghani, M., Nabavifard, M., Hatami, F., Fereidouni, M., Welsh, J. S., & Javadinia, S. A. (2022). Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer investigation, 40(1), 26-34. https://doi.org/10.1080/07357907.2021.1992420
Ariamanesh, Mona, et al. "Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy." Cancer investigation vol. 40,1 (2022): 26-34. doi: https://doi.org/10.1080/07357907.2021.1992420
Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, Hatami F, Fereidouni M, Welsh JS, Javadinia SA. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Invest. 2022 Jan;40(1):26-34. doi: 10.1080/07357907.2021.1992420. Epub 2021 Oct 26. PMID: 34634986; PMCID: PMC8567287.
Copy Download .nbib Format: NLM
Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy.

Cancer investigation

Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, Hatami F, Fereidouni M, Welsh JS, Javadinia SA.
PMID: 34634986
Cancer Invest. 2021 Oct 26;1-9. doi: 10.1080/07357907.2021.1992420. Epub 2021 Oct 26.

OBJECTIVE: To evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients.MATERIAL AND METHOD: 364 cancer patients who received two doses of vaccine were enrolled. The presence of SARS-CoV-2 anti-Spike protein IgG and neutralizing antibody 2...

Cite
Ariamanesh M, Porouhan P, PeyroShabany B, et al. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Invest. 2021;1-9doi: 10.1080/07357907.2021.1992420.
Ariamanesh, M., Porouhan, P., PeyroShabany, B., Fazilat-Panah, D., Dehghani, M., Nabavifard, M., Hatami, F., Fereidouni, M., Welsh, J. S., & Javadinia, S. A. (2021). Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer investigation, 1-9. https://doi.org/10.1080/07357907.2021.1992420
Ariamanesh, Mona, et al. "Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy." Cancer investigation vol. (2021): 1-9. doi: https://doi.org/10.1080/07357907.2021.1992420
Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, Hatami F, Fereidouni M, Welsh JS, Javadinia SA. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Invest. 2021 Oct 26;1-9. doi: 10.1080/07357907.2021.1992420. Epub 2021 Oct 26. PMID: 34634986; PMCID: PMC8567287.
Copy Download .nbib Format: NLM
Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic.

Cancer investigation

Javadinia SA, Ariamanesh M, Nabavifard M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Hatami F, Ghasemi A, Lyman GH, Welsh JS, Ashkar Tizabi S, Dehghani M.
PMID: 34699294
Cancer Invest. 2021 Nov 11;1-9. doi: 10.1080/07357907.2021.1995742. Epub 2021 Nov 11.

Patients with cancer are at significantly greater risk of COVID-19 and its complications than the general population. Since IgG antibodies remain detectable well after infection with the SARS-CoV-2 virus, seroprevalence can be used to estimate the proportion of the...

Cite
Javadinia SA, Ariamanesh M, Nabavifard M, et al. Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer Invest. 2021;1-9doi: 10.1080/07357907.2021.1995742.
Javadinia, S. A., Ariamanesh, M., Nabavifard, M., Porouhan, P., PeyroShabany, B., Fazilat-Panah, D., Hatami, F., Ghasemi, A., Lyman, G. H., Welsh, J. S., Ashkar Tizabi, S., & Dehghani, M. (2021). Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer investigation, 1-9. https://doi.org/10.1080/07357907.2021.1995742
Javadinia, Seyed Alireza, et al. "Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic." Cancer investigation vol. (2021): 1-9. doi: https://doi.org/10.1080/07357907.2021.1995742
Javadinia SA, Ariamanesh M, Nabavifard M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Hatami F, Ghasemi A, Lyman GH, Welsh JS, Ashkar Tizabi S, Dehghani M. Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer Invest. 2021 Nov 11;1-9. doi: 10.1080/07357907.2021.1995742. Epub 2021 Nov 11. PMID: 34699294.
Copy Download .nbib Format: NLM
Low-dose radiation therapy for osteoarthritis and enthesopathies: a review of current data.

International journal of radiation biology

Javadinia SA, Nazeminezhad N, Ghahramani-Asl R, Soroosh D, Fazilat-Panah D, PeyroShabany B, Saberhosseini SN, Mehrabian A, Taghizadeh-Hesary F, Nematshahi M, Dhawan G, Welsh JS, Calabrese EJ, Kapoor R.
PMID: 34259615
Int J Radiat Biol. 2021;97(10):1352-1367. doi: 10.1080/09553002.2021.1956000. Epub 2021 Jul 29.

BACKGROUND: Osteoarthritis (OA), the most common degenerative joint disease, is associated with severe functional limitation and impairment of quality of life. Numerous reports have documented the clinical efficacy of low-dose radiotherapy (LD-RT) in the management of various inflammatory disorders,...

Cite
Javadinia SA, Nazeminezhad N, Ghahramani-Asl R, et al. Low-dose radiation therapy for osteoarthritis and enthesopathies: a review of current data. Int J Radiat Biol. 2021;97(10):1352-1367doi: 10.1080/09553002.2021.1956000.
Javadinia, S. A., Nazeminezhad, N., Ghahramani-Asl, R., Soroosh, D., Fazilat-Panah, D., PeyroShabany, B., Saberhosseini, S. N., Mehrabian, A., Taghizadeh-Hesary, F., Nematshahi, M., Dhawan, G., Welsh, J. S., Calabrese, E. J., & Kapoor, R. (2021). Low-dose radiation therapy for osteoarthritis and enthesopathies: a review of current data. International journal of radiation biology, 97(10), 1352-1367. https://doi.org/10.1080/09553002.2021.1956000
Javadinia, Seyed Alireza, et al. "Low-dose radiation therapy for osteoarthritis and enthesopathies: a review of current data." International journal of radiation biology vol. 97,10 (2021): 1352-1367. doi: https://doi.org/10.1080/09553002.2021.1956000
Javadinia SA, Nazeminezhad N, Ghahramani-Asl R, Soroosh D, Fazilat-Panah D, PeyroShabany B, Saberhosseini SN, Mehrabian A, Taghizadeh-Hesary F, Nematshahi M, Dhawan G, Welsh JS, Calabrese EJ, Kapoor R. Low-dose radiation therapy for osteoarthritis and enthesopathies: a review of current data. Int J Radiat Biol. 2021;97(10):1352-1367. doi: 10.1080/09553002.2021.1956000. Epub 2021 Jul 29. PMID: 34259615.
Copy Download .nbib Format: NLM
A case report of endometrial adenocarcinoma with leptomeningeal metastases.

Clinical case reports

Fazilat-Panah D, Dehghani M, Ahmadi N, Karimi M, Soleimani Varaki S, Emadi Torghabeh A, Mahmoudi H, Keshtpour Amlashi Z, Saghafi M, Fatemi MA, Shokri Bousjin A.
PMID: 34584699
Clin Case Rep. 2021 Sep 21;9(9):e04791. doi: 10.1002/ccr3.4791. eCollection 2021 Sep.

In patients with a history of solid tumors, any new onset of neurological symptoms should be assessed for central nervous system involvement even in rare cases such as gynecological malignancies that nervous system involvement is a rare event.

Cite
Fazilat-Panah D, Dehghani M, Ahmadi N, et al. A case report of endometrial adenocarcinoma with leptomeningeal metastases. Clin Case Rep. 2021;9(9):e04791doi: 10.1002/ccr3.4791.
Fazilat-Panah, D., Dehghani, M., Ahmadi, N., Karimi, M., Soleimani Varaki, S., Emadi Torghabeh, A., Mahmoudi, H., Keshtpour Amlashi, Z., Saghafi, M., Fatemi, M. A., & Shokri Bousjin, A. (2021). A case report of endometrial adenocarcinoma with leptomeningeal metastases. Clinical case reports, 9(9), e04791. https://doi.org/10.1002/ccr3.4791
Fazilat-Panah, Danial, et al. "A case report of endometrial adenocarcinoma with leptomeningeal metastases." Clinical case reports vol. 9,9 (2021): e04791. doi: https://doi.org/10.1002/ccr3.4791
Fazilat-Panah D, Dehghani M, Ahmadi N, Karimi M, Soleimani Varaki S, Emadi Torghabeh A, Mahmoudi H, Keshtpour Amlashi Z, Saghafi M, Fatemi MA, Shokri Bousjin A. A case report of endometrial adenocarcinoma with leptomeningeal metastases. Clin Case Rep. 2021 Sep 21;9(9):e04791. doi: 10.1002/ccr3.4791. eCollection 2021 Sep. PMID: 34584699; PMCID: PMC8455960.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries